Cost-effectiveness Analysis of Ferric Carboxymaltose (Renegy®) for the Treatment of Iron Deficiency Anemia During Pregnancy: The Mexican Social Security Institute (IMSS) Perspective
Author(s)
José Ángel Paladio Hernández, MA, MS1, ROBERTO VALDEZ-HUERTA, BA2, RODRIGO CERVANTES-MORALES, MD3, GERARDO FONTAN TEPICHIN, BA3;
1PALAGOD, Director, Health Economics, MEXICO CITY, Mexico, 2InMarket, Mexico City, Mexico, 3CHINOIN MEXICO, Mexico City, Mexico
1PALAGOD, Director, Health Economics, MEXICO CITY, Mexico, 2InMarket, Mexico City, Mexico, 3CHINOIN MEXICO, Mexico City, Mexico
OBJECTIVES: According to the World Health Organization, anemia affects over 40% of pregnant women worldwide, with iron deficiency accounting for more than 50% of these cases. Intravenous Ferric Carboxymaltose (FCM, Renegy®) offers significant advantages in managing iron deficiency anemia (IDA) during pregnancy, including the ability to deliver high doses of iron in a single session, enabling rapid restoration of iron stores. Additionally, FCM has demonstrated superior tolerability in pregnant women compared to Iron Sucrose Complex (ISC), making it a more patient-centered treatment option. This study assessed the cost-effectiveness of FCM versus ISC for treating IDA during pregnancy from the perspective of the Mexican Social Security Institute (IMSS).
METHODS: A decision tree model was constructed to simulate a cohort of patients over a 12-week time horizon, comparing FCM with ISC. Health outcomes and resource utilization data were primarily sourced from scientific literature. Costs included expenses related to infusions, iron vial acquisition, and adverse event management, with all costs expressed in US dollars. Outcomes were measured as the mean increase in hemoglobin (Hb) levels from baseline after 12 weeks. Probabilistic sensitivity analyses were conducted to assess result robustness.
RESULTS: FCM demonstrated rapid and effective iron replenishment, achieving a significantly greater increase in Hb levels over a 12-week period compared to ISC. FCM proved to be a more cost-effective option, with a total cost per patient of $622.70 compared to $961.50 for ISC. This translates to cost savings of $338.80 per patient, representing a 68.4% reduction in expenses. Probabilistic sensitivity analysis confirmed FCM’s dominance in cost-effectiveness.
CONCLUSIONS: From the IMSS perspective, FCM is a clinically superior and a cost-effective treatment for IDA in pregnant women compared to ISC. Also, FCM offers faster and more significant Hb improvement, better tolerability, and substantial cost savings, solidifying its role as the preferred therapeutic option for managing IDA during pregnancy.
METHODS: A decision tree model was constructed to simulate a cohort of patients over a 12-week time horizon, comparing FCM with ISC. Health outcomes and resource utilization data were primarily sourced from scientific literature. Costs included expenses related to infusions, iron vial acquisition, and adverse event management, with all costs expressed in US dollars. Outcomes were measured as the mean increase in hemoglobin (Hb) levels from baseline after 12 weeks. Probabilistic sensitivity analyses were conducted to assess result robustness.
RESULTS: FCM demonstrated rapid and effective iron replenishment, achieving a significantly greater increase in Hb levels over a 12-week period compared to ISC. FCM proved to be a more cost-effective option, with a total cost per patient of $622.70 compared to $961.50 for ISC. This translates to cost savings of $338.80 per patient, representing a 68.4% reduction in expenses. Probabilistic sensitivity analysis confirmed FCM’s dominance in cost-effectiveness.
CONCLUSIONS: From the IMSS perspective, FCM is a clinically superior and a cost-effective treatment for IDA in pregnant women compared to ISC. Also, FCM offers faster and more significant Hb improvement, better tolerability, and substantial cost savings, solidifying its role as the preferred therapeutic option for managing IDA during pregnancy.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE472
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain), STA: Multiple/Other Specialized Treatments